FIP in Cats: The Disease That Was Once a Death Sentence (New Treatment)

FIP in Cats: The Disease That Was Once a Death Sentence (New Treatment)

By Julia Wrenfield, Pet Wellness Researcher

For decades, feline infectious peritonitis (FIP) was one of the most heartbreaking diagnoses a cat owner could receive. A progressive, invariably fatal disease, FIP meant that even young, otherwise healthy cats would decline and die within weeks to months of diagnosis, with nothing medicine could offer beyond palliative comfort. That reality has now fundamentally changed. The development of antiviral nucleoside analog drugs — most prominently GS-441524 — has transformed FIP from a death sentence into a treatable, often curable disease. Understanding this disease and its new treatment options is essential knowledge for any cat owner today.

What Is FIP?

FIP is caused by a mutated form of feline coronavirus (FCoV). This is not the same virus as SARS-CoV-2; feline coronavirus is common, species-specific, and circulates widely among cats — particularly in multi-cat households and shelters. Most cats infected with FCoV experience only mild gastrointestinal symptoms or no symptoms at all, and their immune systems clear the infection.

In a small percentage of infected cats — estimates range from 5–10% — the virus undergoes a mutation within the body that transforms it from a harmless enteric (gut) virus into a form that replicates inside macrophages (immune cells) and spreads systemically throughout the body. This mutated virus triggers a dysregulated immune response that causes the characteristic lesions of FIP: granulomatous vasculitis (inflammation of blood vessel walls) and pyogranulomatous lesions in affected tissues.

FIP is not directly contagious between cats — the systemic, pathogenic form does not transmit horizontally. What spreads is the common enteric coronavirus, from which FIP can then independently mutate within susceptible individuals. Young cats (under 2 years), cats with suppressed immunity, and cats from high-density environments are at highest risk of developing FIP after FCoV exposure.

Wet (Effusive) vs. Dry (Non-Effusive) FIP

FIP presents in two main clinical forms, though overlap is common and cats may shift between them:

Wet (effusive) FIP is characterized by accumulation of a distinctive amber-colored, protein-rich fluid in body cavities — the abdomen (peritonitis, causing progressive abdominal distension), the chest (pleural effusion, causing labored breathing), or the pericardium. Wet FIP typically progresses rapidly, often over days to weeks. The fluid has a characteristic sticky, viscous quality when sampled.

Dry (non-effusive) FIP produces granulomatous lesions in organs without significant fluid accumulation. It is more chronic and harder to diagnose because it can affect virtually any organ: the eyes (uveitis, chorioretinitis — a common and important sign), brain and spinal cord (neurological FIP with seizures, ataxia, personality changes), kidneys, liver, or lymph nodes. Neurological and ocular FIP are particularly challenging presentations that can mimic many other conditions.

Signs of FIP

FIP signs depend heavily on the form and organs affected, but common findings include:

• Progressive abdominal distension (wet form) or unexplained weight loss
• Persistent fever that does not respond to antibiotics
• Lethargy, inappetence, and failure to thrive — particularly striking in a previously healthy young cat
• Labored breathing (pleural effusion in chest-form wet FIP)
• Eye abnormalities: cloudiness of the cornea, color change in the iris, hypopyon (white material in the eye), or obvious uveitis
• Neurological signs: wobbling gait, falling to one side, head tilt, seizures, behavioral change, paralysis
• Jaundice (liver involvement)
• Enlarged lymph nodes

A classic presentation is a young (often under 2 years), recently adopted or shelter cat who begins to fail despite antibiotic treatment, with persistent fever and a swollen belly. This pattern should prompt FIP testing immediately.

Diagnosis

FIP has historically been one of the most frustrating diagnoses in veterinary medicine because no single test is definitive. Diagnosis involves building a clinical picture from multiple lines of evidence. Key components include: a high coronavirus antibody titer (not specific, but high titers are more suggestive in a compatible clinical picture), characteristic fluid analysis (high protein, high albumin:globulin ratio less than 0.4, the Rivalta test), blood markers including elevated alpha-1-acid glycoprotein (AGP), and complete blood count (nonregenerative anemia, lymphopenia, elevated total protein).

More recently, PCR testing of effusion fluid or cerebrospinal fluid for FCoV RNA, and immunohistochemistry or immunofluorescence of biopsy material, provide higher diagnostic specificity. A definitive diagnosis by biopsy, while ideal, is often not necessary in cases with a very strong clinical picture — especially given that treatment can begin empirically and a positive response itself supports the diagnosis.

The GS-441524 Revolution

GS-441524 is a nucleoside analog antiviral — a compound that interferes with viral RNA replication by incorporating into the viral genome and halting its reproduction. It was developed by Gilead Sciences and showed striking efficacy against FIP in landmark research by Dr. Niels Pedersen at UC Davis, published in 2019. In clinical trials, GS-441524 achieved sustained remission in over 80% of treated cats with wet and dry FIP, including neurological forms (which require higher doses).

Related compounds include GC376 (a protease inhibitor) and the prodrug remdesivir, which is metabolized to GS-441524. As of the time of writing, several branded versions of GS-441524 — including Mutian Xraphconn and NucleoCure — have been used extensively worldwide. Bova Pharmaceuticals in Australia received approval for a licensed veterinary formulation, and regulatory approvals in Europe and the USA are advancing, with Elanco having received FDA approval for a GS-441524-based product. Availability and legal access varies significantly by country; owners in regions without licensed access have historically obtained these compounds through international networks, a practice that carries its own risks but has saved thousands of cats.

Treatment Protocol

The standard treatment protocol consists of 84 days (12 weeks) of daily antiviral medication. Dosing depends on the form and severity:

• Non-effusive (dry) FIP: typically 4–6 mg/kg/day of GS-441524
• Effusive (wet) FIP: 6–8 mg/kg/day
• Neurological or ocular FIP: 8–12 mg/kg/day or higher, as the compound needs to penetrate the blood-brain barrier effectively

Treatment is followed by a 12-week observation period after completing the course. Cats are monitored for relapse during this period; approximately 10–15% of cats require a second course of treatment. The overall sustained remission rate — cats that remain FIP-free after completing treatment and observation — is approximately 85–95% in experienced hands. Regular bloodwork (CBC, chemistry panel, AGP levels) and veterinary monitoring are essential throughout treatment.

Cost Considerations

Treatment cost varies substantially depending on the product used, the cat's weight, the dose required, and the country of access. For a typical 4 kg cat with non-effusive FIP using a licensed product, total treatment can range from €1,500 to €4,000+ over the 84-day course. Neurological FIP requiring higher doses costs more. While this is significant, it should be weighed against the near-certain fatal outcome without treatment. Some advocacy groups and veterinary networks offer support resources for owners facing this financial challenge.

References

1. Pedersen NC, et al. "Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis." Journal of Feline Medicine and Surgery. 2019;21(4):271-281. PMID: 30755069
2. Addie DD, et al. "Recommendations from workshops of the second international symposium on feline coronaviruses." Journal of Feline Medicine and Surgery. 2004;6(2):125-130. PMID: 15123153